331 related articles for article (PubMed ID: 19343618)
1. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
Santarpia L; Habra MA; Jiménez C
Horm Metab Res; 2009 Sep; 41(9):680-6. PubMed ID: 19343618
[TBL] [Abstract][Full Text] [Related]
2. Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas.
Klein RD; Jin L; Rumilla K; Young WF; Lloyd RV
Diagn Mol Pathol; 2008 Jun; 17(2):94-100. PubMed ID: 18382370
[TBL] [Abstract][Full Text] [Related]
3. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma.
Strosberg JR
Semin Oncol; 2013 Feb; 40(1):120-33. PubMed ID: 23391119
[TBL] [Abstract][Full Text] [Related]
4. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
Chrisoulidou A; Kaltsas G; Ilias I; Grossman AB
Endocr Relat Cancer; 2007 Sep; 14(3):569-85. PubMed ID: 17914089
[TBL] [Abstract][Full Text] [Related]
5. Intra-tumoral molecular heterogeneity in benign and malignant pheochromocytomas and extra-adrenal sympathetic paragangliomas.
Korpershoek E; Stobbe CK; van Nederveen FH; de Krijger RR; Dinjens WN
Endocr Relat Cancer; 2010 Sep; 17(3):653-62. PubMed ID: 20488782
[TBL] [Abstract][Full Text] [Related]
6. Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas.
Havekes B; van der Klaauw AA; Weiss MM; Jansen JC; van der Mey AG; Vriends AH; Bonsing BA; Romijn JA; Corssmit EP
Endocr Relat Cancer; 2009 Jun; 16(2):527-36. PubMed ID: 19289533
[TBL] [Abstract][Full Text] [Related]
7. Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach.
Andersen KF; Altaf R; Krarup-Hansen A; Kromann-Andersen B; Horn T; Christensen NJ; Hendel HW
Cancer Treat Rev; 2011 Apr; 37(2):111-9. PubMed ID: 20675056
[TBL] [Abstract][Full Text] [Related]
8. Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior.
Geli J; Kiss N; Karimi M; Lee JJ; Bäckdahl M; Ekström TJ; Larsson C
Clin Cancer Res; 2008 May; 14(9):2551-9. PubMed ID: 18451216
[TBL] [Abstract][Full Text] [Related]
9. Pheochromocytoma and paraganglioma: recent progress and new vistas for improved patient care.
Eisenhofer G; Schott M; Bornstein S
Horm Metab Res; 2012 May; 44(5):325-7. PubMed ID: 22566193
[No Abstract] [Full Text] [Related]
10. Molecular markers of paragangliomas/pheochromocytomas.
Zhikrivetskaya SO; Snezhkina AV; Zaretsky AR; Alekseev BY; Pokrovsky AV; Golovyuk AL; Melnikova NV; Stepanov OA; Kalinin DV; Moskalev AA; Krasnov GS; Dmitriev AA; Kudryavtseva AV
Oncotarget; 2017 Apr; 8(15):25756-25782. PubMed ID: 28187001
[TBL] [Abstract][Full Text] [Related]
11. A novel candidate region linked to development of both pheochromocytoma and head/neck paraganglioma.
Cascón A; Ruiz-Llorente S; Rodríguez-Perales S; Honrado E; Martínez-Ramírez A; Letón R; Montero-Conde C; Benítez J; Dopazo J; Cigudosa JC; Robledo M
Genes Chromosomes Cancer; 2005 Mar; 42(3):260-8. PubMed ID: 15609347
[TBL] [Abstract][Full Text] [Related]
12. Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies.
Nölting S; Grossman AB
Endocr Pathol; 2012 Mar; 23(1):21-33. PubMed ID: 22391976
[TBL] [Abstract][Full Text] [Related]
13. Genomic Landscape of Pheochromocytoma and Paraganglioma.
Jochmanova I; Pacak K
Trends Cancer; 2018 Jan; 4(1):6-9. PubMed ID: 29413423
[TBL] [Abstract][Full Text] [Related]
14. [Pheochromocytoma and sympathetic paragangliomas].
Zollinger R; Hedinger C
Schweiz Med Wochenschr; 1983 Jul; 113(30):1057-65. PubMed ID: 6623024
[TBL] [Abstract][Full Text] [Related]
15. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics.
Plouin PF; Fitzgerald P; Rich T; Ayala-Ramirez M; Perrier ND; Baudin E; Jimenez C
Horm Metab Res; 2012 May; 44(5):390-9. PubMed ID: 22314389
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
[TBL] [Abstract][Full Text] [Related]
17. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
Guo Z; Lloyd RV
Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
[TBL] [Abstract][Full Text] [Related]
18. High expression of neuropeptide y receptors in tumors of the human adrenal gland and extra-adrenal paraganglia.
Körner M; Waser B; Reubi JC
Clin Cancer Res; 2004 Dec; 10(24):8426-33. PubMed ID: 15623622
[TBL] [Abstract][Full Text] [Related]
19. [Pheochromocytomas and paragangliomas: implications of new insights for diagnosis and treatment].
van der Kleij-Corssmit EP; Havekes B; Vriends AH; Jansen JC; Romijn JA
Ned Tijdschr Geneeskd; 2008 Mar; 152(9):489-93. PubMed ID: 18389879
[TBL] [Abstract][Full Text] [Related]
20. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.
Suh I; Shibru D; Eisenhofer G; Pacak K; Duh QY; Clark OH; Kebebew E
Ann Surg; 2009 Dec; 250(6):983-90. PubMed ID: 19661783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]